STUDIES ON IN-VITRO EFFECT OF PICOTAMIDE ON HUMAN PLATELET-AGGREGATION IN PLATELET-RICH PLASMA AND WHOLE-BLOOD

被引：5

作者：

ANFOSSI, G ^{[1
]}

PARISI, S ^{[1
]}

RUSSO, I ^{[1
]}

MULARONI, EM ^{[1
]}

MASSUCCO, P ^{[1
]}

CAVALOT, F ^{[1
]}

MATTIELLO, L ^{[1
]}

TROVATI, M ^{[1
]}

机构：

[1] IST RIC LPB,CINISELLO BALSAMO,ITALY

来源：

THROMBOSIS RESEARCH | 1995年 / 77卷 / 05期

关键词：

PLATELETS; PLATELET AGGREGATION; THROMBOXANE B-2; PICOTAMIDE; ANTIPLATELET DRUG;

D O I：

10.1016/0049-3848(95)93876-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Picotamide is a new antiaggregating agent influencing the platelet prostaglandin pathway through an inhibition of thromboxane A(2) (TXA(2)) synthesis and a competitive antagonism of platelet TXA, receptors. In the present study, we investigated the in vitro, effect of this drug on human platelet aggregation induced by different agents (adenosine 5'-diphosphate [ADP], collagen, Na arachidonate) both in platelet-rich plasma (PRP; Born's method) and whole blood (WB; impedance method). For each aggregating agent, ED50 value (agonist concentration necessary to induce a maximal aggregation of 50%) was determined in control samples and following addition of different picotamide concentrations on the basis of dose-response curves. Picotamide decreased the response to each aggregating agent in both WE and PRP samples. In WB, 25 mu M picotamide was able to induce a highly significant enhancement of ED50 values for ADP (from 6.6+/-1 mu M to 12.7+/-1.7 mu M, p<0.01), Na arachidonate (from 740+/-240 mu M to 1,080+/-280 mu M, p<0,01) and collagen (from 2.4+/-0.3 mu g/ml to 3.8+/-0.15 mu g/ml, p<0.01). In PRP, the same picotamide concentration significantly enhanced ED50 for each aggregating agent (from 2.0+/-0.1 mu M to 3.1+/-0.3 mu M for ADP, p<0.01; from 960+/-80 mu M to 1,850+/-260 mu M for Na arachidonate, p<0.001; from 3.0+/-0.3 mu g/ml to 5.0+/-0.8 mu g/ml for collagen, p<0.01). Present results show that picotamide effect on platelet response is present also in WB. Data might support the use of picotamide as antiaggregating agent in vascular diseases.

引用

页码：399 / 410

页数：12

共 23 条

[1]

Orzalesi, Selleri, Volpato, Fibrinolysis and inhibition of platelet aggregation by N,N′-bis (3-pycolyl)-4-methoxyisophtalamide (G-137), Prog Chem Fibrinolysis Thrombolysis, pp. 267-269, (1975)

[2]

Schmutzler, Hartmann, Casale, Magliano, Picotamide: effects on coagulation, fibrinolysis and platelet aggregation during prolonged administration in aged, Age Ageing, 7, pp. 246-250, (1978)

[3]

Berrettini, De Cunto, Grasselli, Nenci, Picotamide, a derivative of 4-methoxy-isophthalic acid, inhibits thromboxane synthetase and receptors in vitro and in vivo, Thromb Haemostas, 50, (1983)

[4]

Violi, Ghiselli, Iuliano, Pratico', Alessandri, Balsano, Inhibition by picotamide of thromboxane production in vitro and ex vivo, Eur J Clin Pharmacol, 33, pp. 599-602, (1988)

[5]

Cattaneo, Tenconi, Lecchi, Mannucci, In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production, Thromb Res, 62, pp. 717-724, (1991)

[6]

Gresele, Deckmyn, Arnout, Nenci, Vermylen, Characterization of N,N′-bis (3-pycolyl)-4-methoxy-isophtalamide (Picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets, Thromb Haemostas, 61, pp. 479-484, (1989)

[7]

Modesti, Colella, Abbate, Gensini, Neri Serneri, Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide, Eur J Pharmacol, 169, pp. 85-93, (1989)

[8]

Modesti, Colella, Cecioni, Gensini, Abbate, Neri Serneri, Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor, Br J Clin Pharmacol, 31, pp. 439-443, (1991)

[9]

Modesti, Costoli, Cecioni, Colella, Neri Serneri, Relationship between TxA2/PGH2 receptor binding and antiaggregating properties of Picotamide, Thromb Res, 69, (1993)

[10]

Minuz, Lechi, Arosio, Guzzo, Zannoni, Lauciello, Lechi, Effect of picotamide on platelet aggregation and on thromboxane A2 production in vivo, Thromb Heamostas, 65, pp. 312-316, (1991)

← 1 2 3 →